secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition II Corp. (DMII)
CIK:        0002040475
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001213900-26-029050
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud

Drugs Made In America Acquisition II Corp. issues $150K convertible bridge note as part of $1.4M financing
--------------------------------------------------------------------------------

- On March 11, 2026, Company issued a $150,000 unsecured convertible bridge note to Alpha Multi Family Office (Investor).
- The bridge note is part of a larger $1,400,000 convertible notes financing under a Letter of Intent dated March 5, 2026 and an addendum dated March 9, 2026.
- The note matures nine months from issuance, bears no interest, and is convertible at a 35% discount to market price upon a business combination.
- The Company plans to use proceeds for accounting, audit, and other expenses related to the business combination.
- The LOI originally contemplated $1,500,000 but was reduced to $1,400,000 after $100,000 in advisor fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/0001213900-26-029050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2040475/000121390026029050/ea0281959-8k_drugs2.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-029050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer